Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come — Jean Yves Blay (2024) | RDL Network
Jean Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Hénon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard,
Axel Le Cesne, Sylvie Chabaud, O. Bouche, Nicolas Penel, Mehdi Brahmi, Maud Toulmonde, Emmanuelle Bompas, François Bertucci, L. Chaigneau, W. Lahlou, B. Landi, B. Verret, Clémence Hénon, Diane Pannier, Marc Pracht, Olivier Collard, Isabelle Laure Ray-Coquard, Séverine Metzger, David Pérol, Jean Yves Blay
Axel Le Cesne, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Antoine Adenis, Isabelle Ray‐Coquard, Séverine Metzger, Sylvie Chabaud, David Pérol, Jean Yves Blay
Discussion(0)
No comments yet. Be the first to comment.